{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T18:00:57Z","timestamp":1794592857088,"version":"4.9.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s11914-016-0298-z","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T02:59:26Z","timestamp":1456887566000},"page":"10-15","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1"],"prefix":"10.1007","volume":"14","author":[{"given":"Steven D.","family":"Rhodes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,2]]},"reference":[{"key":"298_CR1","volume-title":"Neurofibromatosis: phenotype, natural history, and pathogenesis","author":"J Friedman","year":"1999","unstructured":"Friedman J et al. Neurofibromatosis: phenotype, natural history, and pathogenesis. 3rd ed. Baltimore: The Johns Hopkins University Press; 1999.","edition":"3"},{"issue":"4","key":"298_CR2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(90)90150-D","volume":"63","author":"GA Martin","year":"1990","unstructured":"Martin GA et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990;63(4):843\u20139.","journal-title":"Cell"},{"issue":"4","key":"298_CR3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0092-8674(90)90151-4","volume":"63","author":"R Ballester","year":"1990","unstructured":"Ballester R et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 1990;63(4):851\u20139.","journal-title":"Cell"},{"issue":"27","key":"298_CR4","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJM198112313052704","volume":"305","author":"VM Riccardi","year":"1981","unstructured":"Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med. 1981;305(27):1617\u201327.","journal-title":"N Engl J Med"},{"issue":"2","key":"298_CR5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U","volume":"70","author":"JM Friedman","year":"1997","unstructured":"Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet. 1997;70(2):138\u201343.","journal-title":"Am J Med Genet"},{"issue":"1","key":"298_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8","volume":"89","author":"JM Friedman","year":"1999","unstructured":"Friedman JM. Epidemiology of neurofibromatosis type 1. Am J Med Genet. 1999;89(1):1\u20136.","journal-title":"Am J Med Genet"},{"issue":"5","key":"298_CR7","first-page":"1573","volume":"62","author":"RE Ferner","year":"2002","unstructured":"Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62(5):1573\u20137.","journal-title":"Cancer Res"},{"issue":"5","key":"298_CR8","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/S0022-3476(89)80137-4","volume":"114","author":"R Listernick","year":"1989","unstructured":"Listernick R et al. Optic gliomas in children with neurofibromatosis type 1. J Pediatr. 1989;114(5):788\u201392.","journal-title":"J Pediatr"},{"issue":"1","key":"298_CR9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-3476(94)70122-9","volume":"125","author":"R Listernick","year":"1994","unstructured":"Listernick R et al. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr. 1994;125(1):63\u20136.","journal-title":"J Pediatr"},{"issue":"9","key":"298_CR10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199403033300912","volume":"330","author":"GM Brodeur","year":"1994","unstructured":"Brodeur GM. The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. N Engl J Med. 1994;330(9):637\u20139.","journal-title":"N Engl J Med"},{"issue":"24","key":"298_CR11","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJM199706123362404","volume":"336","author":"L Side","year":"1997","unstructured":"Side L et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med. 1997;336(24):1713\u201320.","journal-title":"N Engl J Med"},{"issue":"10","key":"298_CR12","first-page":"1017","volume":"19","author":"PD Emanuel","year":"1991","unstructured":"Emanuel PD et al. The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia. Exp Hematol. 1991;19(10):1017\u201324.","journal-title":"Exp Hematol"},{"issue":"7","key":"298_CR13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1212\/01.wnl.0000179303.72345.ce","volume":"65","author":"SL Hyman","year":"2005","unstructured":"Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology. 2005;65(7):1037\u201344.","journal-title":"Neurology"},{"issue":"2","key":"298_CR14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/1096-8628(20001113)95:2<108::AID-AJMG4>3.0.CO;2-0","volume":"95","author":"AE Lin","year":"2000","unstructured":"Lin AE et al. Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1. Am J Med Genet. 2000;95(2):108\u201317.","journal-title":"Am J Med Genet"},{"issue":"8-9","key":"298_CR15","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s004679900260","volume":"14","author":"E Fossali","year":"2000","unstructured":"Fossali E et al. Renovascular disease and hypertension in children with neurofibromatosis. Pediatr Nephrol. 2000;14(8-9):806\u201310.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"298_CR16","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1086\/320121","volume":"68","author":"SA Rasmussen","year":"2001","unstructured":"Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet. 2001;68(5):1110\u20138.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"298_CR17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00125817-200205000-00002","volume":"4","author":"JM Friedman","year":"2002","unstructured":"Friedman JM et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med. 2002;4(3):105\u201311.","journal-title":"Genet Med"},{"issue":"4","key":"298_CR18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00467-003-1397-5","volume":"19","author":"G Lama","year":"2004","unstructured":"Lama G et al. Blood pressure and cardiovascular involvement in children with neurofibromatosis type1. Pediatr Nephrol. 2004;19(4):413\u20138.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"298_CR19","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.1542\/peds.2009-0152","volume":"124","author":"D Rea","year":"2009","unstructured":"Rea D et al. Cerebral arteriopathy in children with neurofibromatosis type 1. Pediatrics. 2009;124(3):e476\u201383.","journal-title":"Pediatrics"},{"issue":"9","key":"298_CR20","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s00198-005-1940-2","volume":"16","author":"M Lammert","year":"2005","unstructured":"Lammert M et al. Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int. 2005;16(9):1161\u20136.","journal-title":"Osteoporos Int"},{"issue":"8","key":"298_CR21","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s00198-004-1801-4","volume":"16","author":"T Kuorilehto","year":"2005","unstructured":"Kuorilehto T et al. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int. 2005;16(8):928\u201336.","journal-title":"Osteoporos Int"},{"issue":"4","key":"298_CR22","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/01.bpb.0000271310.87997.ae","volume":"27","author":"S Dulai","year":"2007","unstructured":"Dulai S et al. Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J Pediatr Orthop. 2007;27(4):472\u20135.","journal-title":"J Pediatr Orthop"},{"issue":"8","key":"298_CR23","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1651-2227.2007.00401.x","volume":"96","author":"K Yilmaz","year":"2007","unstructured":"Yilmaz K et al. Bone mineral density in children with neurofibromatosis 1. Acta Paediatr. 2007;96(8):1220\u20132.","journal-title":"Acta Paediatr"},{"issue":"1","key":"298_CR24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpeds.2006.10.048","volume":"150","author":"DA Stevenson","year":"2007","unstructured":"Stevenson DA et al. Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr. 2007;150(1):83\u20138.","journal-title":"J Pediatr"},{"issue":"4","key":"298_CR25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/jmg.2008.061895","volume":"46","author":"T Tucker","year":"2009","unstructured":"Tucker T et al. Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet. 2009;46(4):259\u201365.","journal-title":"J Med Genet"},{"key":"298_CR26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00003086-198908000-00007","volume":"245","author":"AH Crawford","year":"1989","unstructured":"Crawford AH. Pitfalls of spinal deformities associated with neurofibromatosis in children. Clin Orthop Relat Res. 1989;245:29\u201342.","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"298_CR27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/01241398-198601000-00015","volume":"6","author":"AH Crawford Jr","year":"1986","unstructured":"Crawford Jr AH, Bagamery N. Osseous manifestations of neurofibromatosis in childhood. J Pediatr Orthop. 1986;6(1):72\u201388.","journal-title":"J Pediatr Orthop"},{"issue":"10","key":"298_CR28","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s001980170032","volume":"12","author":"T Illes","year":"2001","unstructured":"Illes T et al. Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos Int. 2001;12(10):823\u20137.","journal-title":"Osteoporos Int"},{"issue":"4","key":"298_CR29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/(SICI)1096-8628(19991203)87:4<317::AID-AJMG7>3.0.CO;2-X","volume":"87","author":"M Clementi","year":"1999","unstructured":"Clementi M et al. Neurofibromatosis type 1 growth charts. Am J Med Genet. 1999;87(4):317\u201323.","journal-title":"Am J Med Genet"},{"issue":"12","key":"298_CR30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1136\/jmg.37.12.933","volume":"37","author":"J Szudek","year":"2000","unstructured":"Szudek J, Birch P, Friedman JM. Growth in North American white children with neurofibromatosis 1 (NF1). J Med Genet. 2000;37(12):933\u20138.","journal-title":"J Med Genet"},{"issue":"Suppl 2","key":"298_CR31","first-page":"289","volume":"16","author":"R Virdis","year":"2003","unstructured":"Virdis R et al. Growth and pubertal disorders in neurofibromatosis type 1. J Pediatr Endocrinol Metab. 2003;16 Suppl 2:289\u201392.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"298_CR32","unstructured":"Riccardi VM. Neurofibromatosis: phenotype, natural history, and pathogenesis. 2nd ed. 1992, Baltimore: Johns Hopkins University Press. ix, 498 p."},{"issue":"5","key":"298_CR33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1399-0004.2005.00410.x","volume":"67","author":"S Alwan","year":"2005","unstructured":"Alwan S, Tredwell SJ, Friedman JM. Is osseous dysplasia a primary feature of neurofibromatosis 1 (NF1)? Clin Genet. 2005;67(5):378\u201390.","journal-title":"Clin Genet"},{"issue":"10","key":"298_CR34","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/ajmg.a.33045","volume":"149A","author":"F Elefteriou","year":"2009","unstructured":"Elefteriou F et al. Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A. 2009;149A(10):2327\u201338.","journal-title":"Am J Med Genet A"},{"key":"298_CR35","unstructured":"Young H, Hyman S, North K, Neurofibromatosis 1: clinical review and exceptions to the rules. J Child Neurol. 2002. 17(8):613-21. discussion 627-9, 646-51."},{"key":"298_CR36","doi-asserted-by":"crossref","unstructured":"Friedman JM. Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol. 2002. 17(8):548-54. discussion 571-2, 646-51.","DOI":"10.1177\/088307380201700802"},{"issue":"5","key":"298_CR37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/(SICI)1096-8628(19990611)84:5<413::AID-AJMG5>3.0.CO;2-1","volume":"84","author":"DA Stevenson","year":"1999","unstructured":"Stevenson DA et al. Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet. 1999;84(5):413\u20139.","journal-title":"Am J Med Genet"},{"issue":"6","key":"298_CR38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1203\/PDR.0b013e31816fee45","volume":"63","author":"DA Stevenson","year":"2008","unstructured":"Stevenson DA et al. Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis. Pediatr Res. 2008;63(6):697\u2013701.","journal-title":"Pediatr Res"},{"key":"298_CR39","doi-asserted-by":"crossref","unstructured":"Heerva E et al. A controlled register based study of 460 neurofibromatosis 1 (NF1) patients: Increased fracture risk in children and adults over 41 years. J Bone Miner Res. 2012. A large cohort clinical study shows that patients with NF1 have increased fracture risk depending on age due to decreased bone mass.","DOI":"10.1002\/jbmr.1685"},{"issue":"22","key":"298_CR40","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1242\/dev.125.22.4359","volume":"125","author":"MM Lakkis","year":"1998","unstructured":"Lakkis MM, Epstein JA. Neurofibromin modulation of ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development. 1998;125(22):4359\u201367.","journal-title":"Development"},{"issue":"19","key":"298_CR41","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1093\/hmg\/ddl208","volume":"15","author":"X Wu","year":"2006","unstructured":"Wu X et al. Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem\/progenitor cells. Hum Mol Genet. 2006;15(19):2837\u201345.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"298_CR42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1086\/504441","volume":"79","author":"DA Stevenson","year":"2006","unstructured":"Stevenson DA et al. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet. 2006;79(1):143\u20138.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"298_CR43","doi-asserted-by":"crossref","first-page":"e24917","DOI":"10.1371\/journal.pone.0024917","volume":"6","author":"X Wu","year":"2011","unstructured":"Wu X et al. The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1. PLoS One. 2011;6(9):e24917.","journal-title":"PLoS One"},{"issue":"8","key":"298_CR44","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/hmg\/ddm032","volume":"16","author":"M Kolanczyk","year":"2007","unstructured":"Kolanczyk M et al. Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet. 2007;16(8):874\u201386.","journal-title":"Hum Mol Genet"},{"issue":"20","key":"298_CR45","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1093\/hmg\/ddr310","volume":"20","author":"W Wang","year":"2011","unstructured":"Wang W et al. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Hum Mol Genet. 2011;20(20):3910\u201324.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"298_CR46","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1203\/PDR.0b013e3181a1c607","volume":"65","author":"H Li","year":"2009","unstructured":"Li H et al. Ras dependent paracrine secretion of osteopontin by Nf1+\/\u2212 osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model. Pediatr Res. 2009;65(6):613\u20138.","journal-title":"Pediatr Res"},{"issue":"6","key":"298_CR47","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cmet.2006.10.010","volume":"4","author":"F Elefteriou","year":"2006","unstructured":"Elefteriou F et al. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab. 2006;4(6):441\u201351.","journal-title":"Cell Metab"},{"issue":"7","key":"298_CR48","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nm.1979","volume":"15","author":"Y Tang","year":"2009","unstructured":"Tang Y et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009;15(7):757\u201365.","journal-title":"Nat Med"},{"key":"298_CR49","doi-asserted-by":"crossref","unstructured":"Rhodes SD et al. Hyperactive transforming growth factor-beta1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model. J Bone Miner Res. 2013;28(12):2476\u201389.","DOI":"10.1002\/jbmr.1992"},{"issue":"3","key":"298_CR50","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.bone.2010.06.001","volume":"47","author":"E Heerva","year":"2010","unstructured":"Heerva E et al. Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. Bone. 2010;47(3):583\u201390.","journal-title":"Bone"},{"issue":"5","key":"298_CR51","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ajmg.a.33965","volume":"155A","author":"DA Stevenson","year":"2011","unstructured":"Stevenson DA et al. Multiple increased osteoclast functions in individuals with neurofibromatosis type 1. Am J Med Genet A. 2011;155A(5):1050\u20139.","journal-title":"Am J Med Genet A"},{"issue":"5","key":"298_CR52","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bone.2005.01.022","volume":"36","author":"X Yu","year":"2005","unstructured":"Yu X et al. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone. 2005;36(5):793\u2013802.","journal-title":"Bone"},{"issue":"11","key":"298_CR53","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1172\/JCI29092","volume":"116","author":"FC Yang","year":"2006","unstructured":"Yang FC et al. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest. 2006;116(11):2880\u201391.","journal-title":"J Clin Invest"},{"key":"298_CR54","doi-asserted-by":"crossref","unstructured":"Rhodes SD, et al. Hyperactive transforming growth factor-beta1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model. J Bone Miner Res. 2013;28(12):2476\u201389.","DOI":"10.1002\/jbmr.1992"},{"key":"298_CR55","doi-asserted-by":"crossref","unstructured":"Rhodes SD et al. Nf1 Haploinsufficiency alters myeloid lineage commitment and function, leading to deranged skeletal homeostasis. J Bone Miner Res. 2015;30(10):1840\u201351. This study demonstrates a critical requirement for Nf1 haploinsufficiency at a more primitive\/progenitor stage of myeloid development in perpetuating osteolytic activity.","DOI":"10.1002\/jbmr.2538"},{"key":"298_CR56","doi-asserted-by":"crossref","unstructured":"Alanne MH, et al. Phenotypic characterization of transgenic mice harboring Nf1(+\/\u2212) or Nf1(\u2212\/\u2212) osteoclasts in otherwise Nf1(+\/+) background. J Cell Biochem. 2012;113(6):2136\u201346.","DOI":"10.1002\/jcb.24088"},{"issue":"3","key":"298_CR57","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/gene.20041","volume":"39","author":"WS Chiu","year":"2004","unstructured":"Chiu WS et al. Transgenic mice that express Cre recombinase in osteoclasts. Genesis. 2004;39(3):178\u201385.","journal-title":"Genesis"},{"issue":"2","key":"298_CR58","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/ng0296-144","volume":"12","author":"G Bollag","year":"1996","unstructured":"Bollag G et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12(2):144\u20138.","journal-title":"Nat Genet"},{"issue":"2","key":"298_CR59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ng0296-137","volume":"12","author":"DA Largaespada","year":"1996","unstructured":"Largaespada DA et al. Nf1 deficiency causes Ras-mediated granulocyte\/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat Genet. 1996;12(2):137\u201343.","journal-title":"Nat Genet"},{"key":"298_CR60","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/1479-5876-11-303","volume":"11","author":"XL Xu","year":"2013","unstructured":"Xu XL et al. Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? J Transl Med. 2013;11:303.","journal-title":"J Transl Med"},{"issue":"3","key":"298_CR61","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bone.2011.12.011","volume":"50","author":"E Heerva","year":"2012","unstructured":"Heerva E et al. Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. Bone. 2012;50(3):798\u2013803.","journal-title":"Bone"},{"issue":"6","key":"298_CR62","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00223-013-9835-2","volume":"94","author":"E Heerva","year":"2014","unstructured":"Heerva E et al. Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months. Calcif Tissue Int. 2014;94(6):608\u201312. This clinical study demonstrated a trend toward increased bone mineral density in five out of six patients with NF1-related osteoporosis following 23\u00a0months of alendronate therapy, although the effect size did not reach statistical significance.","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"298_CR63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00198-009-0933-y","volume":"21","author":"S Seitz","year":"2010","unstructured":"Seitz S et al. High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int. 2010;21(1):119\u201327.","journal-title":"Osteoporos Int"},{"issue":"1","key":"298_CR64","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymgme.2007.12.004","volume":"94","author":"N Brunetti-Pierri","year":"2008","unstructured":"Brunetti-Pierri N et al. Generalized metabolic bone disease in neurofibromatosis type I. Mol Genet Metab. 2008;94(1):105\u201311.","journal-title":"Mol Genet Metab"},{"key":"298_CR65","doi-asserted-by":"crossref","unstructured":"He Y et al. c-Fms signaling mediates neurofibromatosis type-1 osteoclast gain-in-functions. PLoS One. 2012;7(11):e46900. This study reveals that the M-CSF\/c-Fms signaling axis serves as a critical pathway underlying the aberrant functioning Nf1 of haploinsufficient osteoclasts and may provide a potential therapeutic target for treating NF1 associated osteoporosis and osteopenia.","DOI":"10.1371\/journal.pone.0046900"},{"issue":"23","key":"298_CR66","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1093\/hmg\/ddt333","volume":"22","author":"R Sharma","year":"2013","unstructured":"Sharma R et al. Hyperactive Ras\/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice. Hum Mol Genet. 2013;22(23):4818\u201328.","journal-title":"Hum Mol Genet"},{"issue":"14","key":"298_CR67","doi-asserted-by":"crossref","DOI":"10.2106\/JBJS.M.00862","volume":"96","author":"J El-Hoss","year":"2014","unstructured":"El-Hoss J et al. A combination of rhBMP-2 (recombinant human bone morphogenetic protein-2) and MEK (MAP kinase\/ERK kinase) inhibitor PD0325901 increases bone formation in a murine model of neurofibromatosis type I pseudarthrosis. J Bone Joint Surg Am. 2014;96(14), e117.","journal-title":"J Bone Joint Surg Am"},{"issue":"8","key":"298_CR68","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nm.3583","volume":"20","author":"J Croix Ndong de la","year":"2014","unstructured":"de la Croix Ndong J et al. Asfotase-alpha improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1. Nat Med. 2014;20(8):904\u201310.","journal-title":"Nat Med"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-016-0298-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-016-0298-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-016-0298-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:16:39Z","timestamp":1654474599000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-016-0298-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["298"],"URL":"https:\/\/doi.org\/10.1007\/s11914-016-0298-z","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}